ADRX logo

ADARX PHARMACEUTICALS INC

ADRXNASDAQ
🏆 #1924 by market capUS Equity
$17.78▼ $0.17 (−0.97%)
Latest quote
🔔
Track ADRX
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 1.0%
7d▲ 0.7%
14d▲ 0.9%
30d▼ 13.9%
ytd—
1y—
🏦Market Cap
$1.97B
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
—
Otter Score
—
Insufficient data

Trading Snapshot

Day Range
$17.72 – $18.00
52-Week Range
$16.61 – $23.21
Volume (shares)
4,477
Avg Volume (shares)
—
Shares Outstanding
110.7M
Next Earnings
—

Fundamentals Snapshot

Annual Revenue
—
Last Q Revenue
—
P/E Ratio
—
P/S Ratio
—
EPS (TTM)
—
Dividend Yield
—
ADRX logo

ADARX PHARMACEUTICALS INC

ADRX
Financial Trends

Financial history unavailable.

StockOtter · stockotter.space

About ADARX PHARMACEUTICALS INC

ADARx Pharmaceuticals, Inc. is a late-clinical-stage biotechnology company. It focuses on developing next-generation small interfering RNA (siRNA) therapeutics for diseases with significant unmet medical needs. The company was founded by Zhen Li in December 2019 and is headquartered in San Diego, CA.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

Overall Score
Insufficient data
—/100
Analyst data unavailable.

Latest News & Updates

GlobeNewsWire·27d ago

ADARx Pharmaceuticals Announces the Closing of Full Exercise of Underwriters' Option to Purchase Additional Shares Granted in Its Initial Public Offering

ADARx Pharmaceuticals Announces the Closing of Full Exercise of Underwriters' Option to Purchase Additional Shares Granted in Its Initial Public Offering

GuruFocus·29d ago

First Look: Disney Layoffs, Apple Smart Home Launch, Goldman CEO Talks

Prefer to listen? Hear this as a ~5-minute audio briefing on The GuruFocus Brief.Stock NewsKen Griffin donates $3B to Carnegie Mellon: Citadel CEO Ken Griffin p

Reuters·Sep 25

ADARx Pharmaceuticals raises $446.3 million in upsized US IPO

ADARx Pharmaceuticals said on Thursday it had raised $446.3 million in an upsized US initial public offering, reflecting ​growing investor appetite for biotech listings.

GlobeNewsWire·Sep 24

ADARx Pharmaceuticals Announces Pricing of Upsized $446.3 Million Initial Public Offering

SAN DIEGO, Sept. 24, 2026 (GLOBE NEWSWIRE) -- ADARx Pharmaceuticals, Inc. (ADARx), a late-stage clinical biotechnology company developing next-generation siRNA therapeutics, announced today the pricing of its upsized ini